February 25, 2021
Research agreement focuses on battlefield injuries
WEST LAFAYETTE, Ind. – OYE Therapeutics Inc., a Purdue University-affiliated company, is working to reduce the mortality and morbidity resulting from injuries on the battlefield through the development of new life-saving strategies.
OYE is located in the Purdue Technology Center in the Purdue Research Park of Northwest Indiana.
The company has entered into a Cooperative Research and Development Agreement (CRADA) with the Uniformed Services University of the Health Sciences (USU), an institution of higher learning within the U.S. Department of Defense and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF).
The partnership includes researching the effectiveness of OYE-002 to enhance acute pain control at the point-of-injury, cognitive processing, psychomotor resilience and mission capabilities.
“An aspect of this CRADA is to evaluate peer-reviewed medical literature to assess OYE’s drug product pipeline for potential in military medicine,” said Dr. Jong Lee, an assistant professor of anesthesiology at USU.
Capt. Dr. Arlene Hudson, chair of anesthesiology at USU, said, “This project seeks to address a medical gap in care and meet the unique demands of warfighters.”
The collaboration between USU and HJF has the potential to encompass multiple future projects, with the ultimate objective of enabling drug development to save the lives of American military personnel worldwide and translating the results to civilian care. Target indications for OYE include adjunctive pain control, restoration of cognitive and psychomotor function, anesthesia, trauma and acute respiratory distress syndrome.
“Collaborating with USU and HJF is an important milestone for OYE, as the company has been working on and filed patent applications to extend the capabilities of our current lead candidate, OYE-001, for both civilian and government use,” said Brett Dines, chief executive officer of OYE Therapeutics. “It is intended that the results of the work on OYE-002 will support our continued effort to expand OYE’s pipeline and potential to speed the development and accelerate drug product approvals for innovative indications addressing gaps in medical care under the U.S. FDA’s 505(b)2 regulatory approval process for civilian and DoD clinical use.”
About OYE Therapeutics Inc.
OYE Therapeutics is focused on bringing health care innovation to market to meet gaps in care through the U.S. Food and Drug Administration's 505(b)2 regulatory approval process. Pipeline candidates consist primarily of new indications for existing drug products that have established pre-clinical and safety profiles allowing for the safe and expedited approval of the new indications as covered by section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. The clinical innovation of the pipeline offers improvements in safety, clinical effectiveness and financial benefit fulfilling the triple aim in health care. The mission of the company is to improve lives by accelerating innovative solutions to market under the U.S. FDA’s 505(b)2 process. OYE’s lead candidate, OYE-001, is a Phase II/III asset indicated for reversing the effects of general anesthesia, a first-in-class agent, seeking to improve upon patient safety at emergence from anesthesia, overall reduction in recovery room length of stay, and restoration of cognitive and motor skills. Readout of OYE-001’s Phase II clinical study is anticipated Q1-2022.
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. is a global nonprofit that administers more than $500 million in medical research funds annually. For more than 35 years, HJF has partnered with researchers and clinicians to provide bench to bedside to battlefield research support. More than 3,000 HJF teammates ensure HJF is a trusted and responsive partner by providing scientific, administrative and program operations services to researchers in the military, academia, and private industry. For more information, visit hjf.org.
About Purdue Research Foundation
Purdue Research Foundation supports Purdue University’s land-grant mission by helping the university improve the world through its technologies and graduates. Established in 1930, PRF is a private, nonprofit foundation. The foundation helps patent and commercialize Purdue technologies; builds places to encourage innovation, invention, investment, commercialization and entrepreneurship; and makes equity available to students to finance their Purdue education. For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at firstname.lastname@example.org. For more information about involvement and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at email@example.com.
Special note regarding forward-looking statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. OYE does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.